Veoza - direct healthcare professional communication (DHPC)

fezolinetant

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Veoza (fezolinetant): risk of drug-induced liver injury and new recommendations on monitoring of liver function before and during treatment

Key facts

• Medicine name:
  Veoza
• Active substance:
  fezolinetant
• Therapeutic area (MeSH):
  • Menopause
  • Hot Flashes
• Procedure number:
  PSUSA/00000231/202405
• Regulatory outcome:
  Variation
• DHPC type:
  Adverse event
• Human ATC codes:
  G02CX06
• Dissemination date:
  13/01/2025